German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs

被引：30

作者：

Albrecht, Katinka t ^{[1
]}

Krueger, Klaus ^{[2
]}

Wollenhaupt, Juergen ^{[3
]}

Alten, Rieke ^{[4
]}

Backhaus, Marina ^{[5
,6
]}

Baerwald, Christoph ^{[7
]}

Bolten, Wolfgang ^{[8
]}

Braun, Juergen ^{[9
]}

Burkhardt, Harald ^{[10
]}

Burmester, Gerd R. ^{[5
,6
]}

Gaubitz, Markus ^{[11
]}

Gause, Angela ^{[12
]}

Gromnica-Ihle, Erika ^{[13
]}

Kellner, Herbert ^{[14
,15
]}

Kuipers, Jens ^{[16
]}

Krause, Andreas ^{[17
]}

Lorenz, Hans-Martin ^{[18
]}

Manger, Bernhard ^{[19
]}

Nuesslein, Hubert

Pott, Hans-Georg

Rubbert-Roth, Andrea ^{[20
]}

Schneider, Matthias ^{[21
]}

Specker, Christof ^{[22
]}

Schulze-Koops, Hendrik ^{[23
]}

Tony, Hans-Peter ^{[24
]}

Wassenberg, Siegfried ^{[25
]}

Mueller-Ladner, Ulf ^{[26
]}

机构：

[1] German Soc Rheumatol, Berlin, Germany

[2] Ctr Rheumatol, Munich, Germany

[3] Schoen Hosp, Hamburg, Germany

[4] Univ Med Berlin, Schlosspk Clin, Dept Internal Med, Berlin, Germany

[5] Free Univ Berlin, Charite Univ Med Berlin, Dept Rheumatol & Clin Immunol, Berlin, Germany

[6] Humboldt Univ, D-10099 Berlin, Germany

[7] Univ Leipzig, Dept Rheumatol & Gerontol, D-04109 Leipzig, Germany

[8] Klaus Miehlke Hosp, Dept Internal Med & Rheumatol, Wiesbaden, Germany

[9] St Josef Hosp, Ctr Rheumatol Ruhr, Herne, Germany

[10] Goethe Univ Frankfurt, Dept Rheumatol, Frankfurt, Germany

[11] WWU, Munster, Germany

[12] Ctr Rheumatol & Autoimmunol, Hamburg, Germany

[13] German League Rheumatism, Bonn, Germany

[14] Hosp Neuwittelsbach, Munich, Germany

[15] Hosp Neuwittelsbach, Dept Rheumatol, Munich, Germany

[16] Red Cross Hosp, Dept Internal Rheumatol, Bremen, Germany

[17] Immanuel Hosp, Dept Rheumatol, Berlin, Germany

[18] Heidelberg Univ, Dept Med 5, Div Rheumatol, Heidelberg, Germany

[19] Univ Erlangen Nurnberg, Dept Rheumatol, D-91054 Erlangen, Germany

[20] Univ Cologne, Dept Immunol & Rheumatol, D-50931 Cologne, Germany

[21] Univ Dusseldorf, Dept Rheumatol, Dusseldorf, Germany

[22] Kliniken Essen Sud, Dept Rheumatol & Clin Immunol, Essen, Germany

[23] LMU Munchen, Med Klin & Poliklin 4, Div Rheumatol & Clin Immunol, Munich, Germany

[24] Univ Wurzburg, Dept Rheumatol & Clin Immunol, D-97070 Wurzburg, Germany

[25] Evangel Fachkrankenhaus Ratingen, Ratingen, Germany

[26] Univ Giessen, Kerckhoff Klin, Dept Rheumatol & Clin Immunol, Bad Nauheim, Germany

来源：

RHEUMATOLOGY INTERNATIONAL | 2014年 / 34卷 / 01期

关键词：

Rheumatoid arthritis; Clinical practice guideline; Disease-modifying antirheumatic drugs; Glucocorticoids; Biologic agents; EULAR RECOMMENDATIONS; DOUBLE-BLIND; METHOTREXATE; MANAGEMENT; REMISSION; THERAPY; COMBINATION; 2-YEAR; CYCLOSPORINE; LEFLUNOMIDE;

D O I：

10.1007/s00296-013-2848-3

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

The German Society of Rheumatology approved new German guidelines for the sequential medical treatment of rheumatoid arthritis (RA) based on the European League Against Rheumatism (EULAR) recommendations for the management of RA published in 2010. An update of the EULAR systematic literature research was performed in Medline, Embase, and Cochrane databases. Meta-analyses, controlled trials, cohort studies, and registry data addressing traditional and biologic disease-modifying antirheumatic drugs, glucocorticoids, and treatment strategies published between January 2009 and August 2011 were included. Two reviewers independently evaluated and compared the additional data that had been published after the time limit set by the EULAR recommendations. A national guideline working group developed an adapted set of recommendations. The new German guidelines were accepted by vote using an informal Delphi approach. Twelve recommendations and the resulting updated treatment algorithm were developed and approved as a practical orientation for rheumatologists. These recommendations are based on a successive treatment with traditional and biologic disease-modifying drugs depending on the individual progress of the disease and distinct patient characteristics. The German guidelines have been developed on the basis of the internationally well-recognized EULAR recommendations. In addition, more recent evidence from a systematic literature research was considered. They have been developed and approved by a group of national experts aiming at guidance for rheumatologists to reach best medical practice.

引用

页码：1 / 9

页数：9

共 42 条

[1]

Albrecht K, 2012, Z RHEUMATOL, V71, P604, DOI 10.1007/s00393-012-1048-y

[2]

[Anonymous], OXF 2011 LEV EV

[3]

Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes [J].

Bathon, J. ;

Robles, M. ;

Ximenes, A. C. ;

Nayiager, S. ;

Wollenhaupt, J. ;

Durez, P. ;

Gomez-Reino, J. ;

Grassi, W. ;

Haraoui, B. ;

Shergy, W. ;

Park, S-H ;

Genant, H. ;

Peterfy, C. ;

Becker, J-C ;

Covucci, A. ;

Reed, D. Moniz ;

Helfrick, R. ;

Westhovens, R. .

ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (11) :1949-1956

[4]

Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration [J].

Chatzidionysiou, Katerina ;

Lie, Elisabeth ;

Nasonov, Evgeny ;

Lukina, Galina ;

Hetland, Merete Lund ;

Tarp, Ulrik ;

van Riel, Piet L. C. M. ;

Nordstrom, Dan C. ;

Gomez-Reino, Juan ;

Pavelka, Karel ;

Tomsic, Matija ;

Kvien, Tore K. ;

van Vollenhoven, Ronald F. ;

Gabay, Cem .

ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (03) :374-377

[5]

Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial [J].

Curtis, Jeffrey R. ;

Yang, Shuo ;

Chen, Lang ;

Park, Grace S. ;

Bitman, Bojena ;

Wang, Brian ;

Navarro-Millan, Iris ;

Kavanaugh, Arthur .

ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (02) :206-212

[6]

De Boer K.V., 2010, Arthritis Rheum, V62, P1396

[7]

Effectiveness of Biologic Therapies for Rheumatoid Arthritis: An Indirect Comparisons Approach [J].

Devine, Emily Beth ;

Alfonso-Cristancho, Rafael ;

Sullivan, Sean D. .

PHARMACOTHERAPY, 2011, 31 (01) :39-51

[8]

Dougados M., 2011, Ann Rheum Dis, V70, P73

[9]

The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study [J].

Finckh, A. ;

Dehler, S. ;

Gabay, C. .

ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (01) :33-39

[10]

Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis [J].

Gaujoux-Viala, Cecile ;

Smolen, Josef S. ;

Landewe, Robert ;

Dougados, Maxime ;

Kvien, Tore K. ;

Martin Mola, Emilio ;

Scholte-Voshaar, Marieke ;

van Riel, Piet ;

Gossec, Laure .

ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (06) :1004-1009

← 1 2 3 4 5 →